Bayer AG

Explore how Bayer AG’s UK approval of the high‑margin oncology drug Sevabertinib balances soaring revenue prospects against looming Roundup litigation costs, shaping investor sentiment and future strategy.

Explore Bayer’s latest voting‑rights disclosure, push for streamlined EU regulation and its breakthrough gene‑therapy for heart failure—why these moves matter for investors and patients alike.

Read how Bayer AG’s U.S. restructuring and new leadership aim to slash costs, boost emerging‑market sales, and sustain growth amid patent pressure.

Explore how Bayer AG’s new Japanese approvals, dividend policy, and agricultural innovation shape its future growth, earnings, and investor outlook.

Explore Bayer AG’s strategic realignment: share sale, labor cost stability, and breakthrough biologics like BAY‑001 for metastatic melanoma and BAY‑002 for diabetes, plus a crop‑protection partnership, all aimed at boosting financial health and scie…

Explore how Bayer AG’s life‑science focus shields its shares from oil‑price swings and what the upcoming earnings may reveal about resilience amid geopolitical risk.

Discover how Bayer’s new renal‑cardio drug and contrast‑media expansion is reshaping investor sentiment, boosting earnings, and positioning the company for long‑term growth.

Explore how Bayer AG’s specialty implant strategy drives 13 % core sales growth and high‑teens EBITDA, backed by custom‑fit solutions, global expansion, and disciplined cost control.

Explore Bayer AG’s market stance—steady yet flat in a volatile German market, with growth plateaued but green chemistry and digital health offering new prospects.

Provisional U.S. court approval of Bayer’s multi‑billion‑dollar Roundup settlement: financial impact, market reaction, and future risk for the agribusiness giant.